In summary, we report CASC11, which was modulated by YY1, plays a crucial role in promoting HCC progression by recruiting EIF4A3 to affect E2F1 and then further impacting the activation of NF‐κB signaling and PI3K/AKT/mTOR pathway (Figure 8). Here, E2F1 is linked to hepatocellular carcinoma.